ImpediMed (ASX:IPD) has commenced enrolment in the first planned clinical study of its “SOZO” device for lymphoedema, a condition that causes swelling in the body's tissues.
SOZO uses bioimpedance spectroscopy (BIS) technology to manage and monitor a person’s fluid status, body composition and hydration in a clinical or at-home setting.
Lymphoedema is a leading post-surgical complication for many breast cancer patients and significantly impacts quality of life.
The accurate measurement of fluid in limbs by SOZO allows early detection and intervention.
Importantly, the aim of this study is to determine the best practices for at-home lymphoedema monitoring.
The study is being led by Louise Koelmeyer, the Lymphoedema Program Manager of Macquarie University Hospital’s ALERT (Australian Lymphoedema Education, Research & Treatment) program.
The ALERT team aims to optimise positive outcomes for people living with lymphoedema through excellence in assessment and management of the condition along the continuum.
Macquarie University has recognised the potential for SOZO to improve the way patients are monitored and has initiated this study to help establish how the at-home program is best implemented.
The aim is to detect lymphoedema at the earliest possible point in its development when its progression can be stopped or even reversed.